

Developers Call FDA Guidance on Suffixes a 'Direct Blow' to Biosimilars

March 8, 2019

ATTORNEYS

Landmon, Chad

PRACTICE AREAS

FDA

Kelly Davio

The Center for Biosimilars

Axinn partner Chad Landmon was quoted in *The Center for Biosimilars* article, "Developers Call FDA Guidance on Suffixes a 'Direct Blow' to Biosimilars."

[Click here to access the article.](#)